Erythropoietic protoporphyria (EPP) is a rare genetic disorder characterized by an abnormal accumulation of protoporphyrin IX, leading to severe skin photosensitivity and potential liver ...

Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA ...

Study: The histamine pathway is a target to treat hepatic experimental erythropoietic protoporphyria. Image Credit: luchschenF/Shutterstock.com In a recent study published in the Cellular and ...

Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021. Erythropoietic protoporphyria (EPP), including X-linked Protoporphyria (XLP), is a rare, debilitating and ...

Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021. Erythropoietic protoporphyria (EPP), including X-linked Protoporphyria (XLP), is a rare, debilitating and ...

Erythropoietic protoporphyria (EPP), including X-linked Protoporphyria (XLP), is a rare, debilitating and potentially life-threatening disease caused by mutations that affect heme biosynthesis ...

focusing on Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP). This progression surfaced as part of a current report on Form 8-K, offering important insights into the company ...

Cautionary Statement Regarding Forward-Looking Statements ...

Inclusion of patients aged 12+ with EPP including X-linked protoporphyria (XLP); and Double-blind, placebo-controlled study with ~150 patients randomized 1:1.